IL-1α-loaded polyanhydride nanoparticles did not affect the anti-tumor efficacy of cetuximab and their combination with cetuximab induced a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs (149). Here, IL1A is linked to neoplasm.